Deferasirox, an iron-chelating agent, as salvage therapy for rhinocerebral mucormycosis [2]

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 11, 2006, Pages 3968-3969

  Reed, Caitlin ^a   Ibrahim, Ashraf ^a   Edwards Jr , John E ^a   Walot, Irwin ^a   Spellberg, Brad ^a  

^a HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; DEFERASIROX; IRON; IRON CHELATING AGENT; METAL COMPLEX; POLYENE;

ADULT; BRAIN DISEASE; CASE REPORT; CHELATION THERAPY; DIABETIC KETOACIDOSIS; DISEASE COURSE; DOSE RESPONSE; HUMAN; HUMAN TISSUE; IRON CHELATION; IRON OVERLOAD; LETTER; MALE; MUCORALES; MUCORMYCOSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RHINOCEREBRAL MUCORMYCOSIS; SALVAGE THERAPY; TREATMENT OUTCOME;

ADULT; AMPHOTERICIN B; ANTIBIOTICS, ANTIFUNGAL; ANTIFUNGAL AGENTS; BENZOIC ACIDS; BRAIN STEM; CAVERNOUS SINUS; CENTRAL NERVOUS SYSTEM FUNGAL INFECTIONS; DIABETIC KETOACIDOSIS; DRUG THERAPY, COMBINATION; HUMANS; IRON CHELATING AGENTS; MAGNETIC RESONANCE IMAGING; MALE; MUCORMYCOSIS; NOSE DISEASES; PEPTIDES, CYCLIC; SALVAGE THERAPY; TRIAZOLES;

EID: 33750583529     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01065-06     Document Type: Letter

References (6)

1. Boelaert, J. R., M. de Locht, J. Van Cutsem, V. Kerrels, B. Cantinieaux, A. Verdonck, H. W. Van Landuyt, and Y. J. Schneider. 1993. Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies. J. Clin. Investig. 91:1979-1986.
2. Boelaert, J. R., J. Van Cutsem, M. de Locht, Y. J. Schneider, and R. R. Crichton. 1994. Deferoxamine augments growth and pathogenicity of Rhizopus, while hydroxypyridinone chelators have no effect. Kidney Int. 45:667-671.
3. Cappellini, M. D. 2005. Iron-chelating therapy with the new oral agent ICL670 (Exjade). Best Pract. Res. Clin. Haematol. 18:289-298.
4. Ibrahim, A. S., J. E. Edwards, Jr., Y. Fu, and B. J. Spellberg. 23 August 2006, posting date. Deferiprone iron chelation as a novel therapy for experimental mucormycosis. J. Antimicrob. Chemother. [Online.] doi:10.1039/jac/dk1350.
5. Spellberg, B., J. Edwards, Jr., and A. Ibrahim. 2005. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin. Microbiol. Rev. 18:556-569.
6. Spellberg, B., Y. Fu, J. E. Edwards, Jr., and A. S. Ibrahim. 2005. Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice. Antimicrob. Agents Chemother. 49:830-832.